NorthWest Biotherapeutics Inc (NWBO)

[iwasadiver]

The new guidance is not an issue; it’s simply kind of like a guarantee against some cowboy FDA bureaucrat thinking he/she’s going to make an attempt at being virtuous in some biased way against NWBO’s trial, or against a new trial trying to start by some other company. That is not going to happen at this point anyway; the trial is way too well known in the scientific community for the FDA to play games. I think it’s quite the opposite actually, and I believe the new guidance is an indicative nod to NWBO that they’ve been watching and have an idea that this technology may be something groundbreaking.

I know that the 30 retail investors out of 14,000 that read and respond on this message board think this board is representative of the reality of NWBO and the trial, but that’s far from the truth. The scientific community, particularly the Glio set, are salivating at what appears to be happening with survival. This will be front page stuff in the New England Journal, the cover story. With that The NY Times, CNN, etc. will blow this to kingdom come. Whatever jitters cause the stuff being said on this board please understand it’s not the view of Physicians and Scientists. The very things stated in the new guidance have already been used widely in the PD-1 trials and have already set a precedent. The guidance is just another notch in the belt and has more to do, in my opinion, with the trials that will commence for expanded L indications and for new and more efficiently produced Direct trials.

I don’t believe there’s any delay by NWBO waiting for the new Guidance to be adopted. I believe this is another narrative either shaky retails investors are nervous about or one put forth by shorts to keep the nerves frayed. The data is solid as we’ve seen. The SAP has been worked through by some of the world’s top clinical statisticians. The game is to measure, re-measure, re-evaluate what you have, cross all the t’s again, dot all the i’s again. Then you take a breath, lock the data, and release it. It’s going to happen. No question in my mind what so ever. This will be the thing investors who’ve stayed the course have dreamed about, the thing patient’s have prayed for, and the thing Big Pharma will want to make their PD-1’s more relevant